scholarly journals The Nationwide Osmed Health-Db Database. A Tool To Support Healthcare Decision-Making And Real-World Evidence Generation

2015 ◽  
Vol 18 (7) ◽  
pp. A693 ◽  
Author(s):  
L Degli Esposti ◽  
S Saragoni ◽  
D Sangiorgi ◽  
S Buda ◽  
A Cangini ◽  
...  
2021 ◽  
Vol 24 ◽  
pp. S194
Author(s):  
L. Costa ◽  
A.L. Hincapie ◽  
R. Gilardino ◽  
B. Tang ◽  
G. Julian ◽  
...  

2020 ◽  
Vol 36 (S1) ◽  
pp. 16-16
Author(s):  
Paola Andrea Rivera-Ramirez ◽  
Fabián Alejandro Fiestas-Saldarriaga

IntroductionIn the absence of direct evidence from randomized controlled trials (RCTs), real-world evidence (RWE) can play an important role in healthcare decision making. As part of a health technology assessment, we assessed the comparative risk of tuberculosis (TB) associated with using infliximab and etanercept in patients with rheumatoid arthritis.MethodsWe performed a systematic literature search using the PubMed database to identify relevant meta-analyses.ResultsWe located two relevant meta-analyses: one based on RCTs and one based on observational studies. Evidence from seven RCTs on infliximab (2,686 patients; 12 TB events) and two RCTs on etanercept (663 patients; 2 TB events) suggested no significant differences in the risk of TB between the two treatments, compared with placebo. In contrast, evidence from ten observational studies that directly compared the two treatments (443,941 patients; 253 TB events) indicated a significantly higher risk of TB with infliximab than with etanercept.ConclusionsAlthough RWE is prone to confounding and bias, in this case it had the advantage of providing direct comparisons with larger sample sizes and longer follow up than evidence from RCTs. As a result, RWE was used to inform decision making on the risk of TB with infliximab and etanercept in patients with rheumatoid arthritis.


2019 ◽  
Vol 22 (6) ◽  
pp. 739-749 ◽  
Author(s):  
Nahila Justo ◽  
Manuel A. Espinoza ◽  
Barbara Ratto ◽  
Martha Nicholson ◽  
Diego Rosselli ◽  
...  

2021 ◽  
Vol 24 ◽  
pp. S157
Author(s):  
H. Monsanto ◽  
C. Parellada ◽  
J. Orengo ◽  
J.S. Velasco ◽  
Bavel J van ◽  
...  

Author(s):  
Inaki Imaz-Iglesia ◽  
Pedro Serrano ◽  
Eugenia Orejas ◽  
Anai Moreno ◽  
Janet Puñal-Ruibóo ◽  
...  

IntroductionA national act (Order SSI/1356/2015) regulating Post-Launch Evidence Generation (PLEG) studies was set in Spain in 2015. These PLEG studies are to inform decisions about technologies already included in the Benefit Portfolio of the Spanish National Health System (SNHS) in order to confirm/exclude/modify their terms of use. Once a PLEG is established the selected hospitals provide the technology according to a common protocol and register outcomes until the required sample size is reached.MethodsThe PLEG studies are prospective, observational and single arm studies on safety, effectiveness and cost-effectiveness of a technology in real practice. The technology is selected because of the identification of an evidence gap, usually through a health technology assessment (HTA) report made by an agency of the Spanish Network of HTA Agencies (RedETS). The execution of a PLEG is assigned to one of the RedETS Agencies, which is responsible of delivering annual reports and a final report when the objectives are reached.ResultsThe following six PLEG studies, all of them on medical devices, have been launched in Spain so far, i) Endobronchial valve for patients with persistent air leak; ii) Biodegradable esophageal stent; iii) Percutaneous mitral valve repair system by clip; iv) Left Atrial Appendage Closure Device; v) Sensor-based glucose monitoring systems for children with type 1 diabetes mellitus; vi) Left ventricular assist devices for destination therapy. Five studies will finish their data collection by the end of 2020 or during 2021.ConclusionsA new national procedure using PLEG has been made available in Spain facilitating the use of real-world evidence to inform national decision-making on the financing of selected technologies due to uncertainties about their effectiveness, safety, cost-effectiveness and organizational impact. The studies are requiring a high amount of coordination tasks, as they are involving an average of 21 hospitals each. The usefulness and suitability of this procedure to achieve its objectives must be evaluated once their results are available.


Sign in / Sign up

Export Citation Format

Share Document